Document:

exv10w1

Exhibit 10.1

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Attention: President and CEO

Santarus, Inc.

3721 Valley Centre Drive, Suite 400

San Diego, California 92130

11th Feb 2011

Dear Sirs,

Amendment to License Agreement dated 9 October 2009

On 9 October 2009 Norgine B.V. (“Norgine”) and Santarus, Inc., (“Santarus”) entered into a License
Agreement (the “Agreement”). Pursuant to Section 15.5.4 of the Agreement, Santarus and Norgine now
wish to amend the Agreement to include European Patent Application No. 07871127.2 (Publication No.
2068841), Great Britain Patent Application No. GB 0719990.4 (Publication No. GB 2444593), and Great
Britain Patent Application No. GB 0910544.6 (Publication No. GB 2459393) as Other Santarus Patents
and to add such patent applications to Exhibit 1.37(B) of the Agreement, and to include European
Patent Application No. 10157716.1 (Publication No. 2201952), European Patent Application No.
10187771.6, Norway Patent Application No. 20023313, and Poland Patent Application No. Pl-357144
(Patent No. 201906) as Missouri Patents and to add such patent applications to Exhibit 1.37(A).
Accordingly it is hereby agreed that Exhibit 1.37(A) and Exhibit 1.37(B) shall now be replaced by
the attached amended and restated Exhibit 1.37(A) and Exhibit 1.37(B)(the “First Amendment”). The
First Amendment shall take effect from the last date of signature below.

This letter shall be governed by, and construed and enforced in accordance with the laws of New
York. Each party submits to the jurisdiction of the courts of New York.

In this letter capitalised words and phrases shall have the same meaning as in the Agreement save
as otherwise set out herein.

	 	 	 

	Yours sincerely
	 	 
	 
	 	 
	/s/ F.P. Nooteboom
 

	 	 
	For and on behalf of Norgine B.V.
	 	 
	 
	 	 
	February 14, 2011
	 	 
	 
	 	 
	Date
	 	 
	 
	 	 
	Acknowledged, agreed and accepted by
	 	 
	 
	 	 
	/S/ Gerald T. Proehl
	 	 
	 
	 	 
	Santarus, Inc.
	 	 
	 
	 	 
	March 3, 2011
	 	 
	 
	 	 
	Date
	 	 

 

 

EXHIBIT 1.37 A(1)

	 	 	 	 	 	 	 	 	 	 	 
	Title	 	Country	 	Application Number	 	Status	 	Ownership
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	01904818.0	 	 	Granted as

 EP1246622(3)
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	04003380.5	 	 	Abandoned
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	02768296.2	 	 	Abandoned
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	03710694.5	 	 	Pending
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	06020125.8	 	 	Abandoned
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	10157716.1	 	 	Pending
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	EPO(2)
	 	 	10187771.6	 	 	Pending
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	Norway(2)
	 	 	20023313	 	 	Pending
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	Poland(2)
	 	PL-357144
	 	Granted as 201906
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Substituted
Benzimidazole
Dosage Forms and
Method of Using
Same

	 	ISRAEL(2)
	 	 	150696	 	 	Pending
	 	Licensed from Univ. Missouri
	 
	 	 	 	 	 	 	 	 	 	 
	A Novel
Formulation,
Omeprazole Antacid
Complex-Immediate
Release for Rapid
and Sustained
Supression of
Gastric Acid

	 	EPO(2)
	 	 	04713382.2	 	 	Pending
	 	Santarus and Univ. Missouri (4) (5)
	 
	 	 	 	 	 	 	 	 	 	 
	A Novel
Formulation,
Omeprazole Antacid
Complex-Immediate
Release for Rapid
and Sustained
Supression of
Gastric Acid

	 	EPO(2)
	 	 	05735477.1	 	 	Pending
	 	Santarus and Univ. Missouri (4) (5)
	 
	 	 	 	 	 	 	 	 	 	 
	Immediate-Release
Formulation of
acid-Labile
Pharmaceutical
Compositions

	 	EPO(2)
	 	 	04778879.9	 	 	Abandoned
	 	Santarus and Univ. Missouri (4) (6)

[***]

[***]

[***]

[***]

[***]

[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT 1.37 B(1)

	 	 	 	 	 	 	 	 	 	 	 
	Title	 	Country	 	Application Number	 	Status	 	Ownership
	Pharmaceutical Formulations Useful for Inhibiting
Acid Secretion and Methods for Making and Using
Them

	 	EPO(2)
	 	 	05755940.3	 	 	Pending
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Pharmaceutical Formulations Useful for Inhibiting
Acid Secretion and Methods for Making and Using
Them

	 	EPO(2)
	 	 	04778425.1	 	 	Pending
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Pharmaceutical Formulation and Method for
Treating Acid-Caused Gastrointestnal Disorders

	 	EPO(2)
	 	 	04778512.6	 	 	Pending
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Combination of Proton Pump Inhibitor and Sleep Aid

	 	EPO(2)
	 	 	04818347.9	 	 	Abandoned
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Combination of Proton Pump Inhibitor, Buffering
Agent and Nonsteroidal anti-inflammatory agent

	 	EPO(2)
	 	 	05722791.0	 	 	Pending
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Combination of Proton Pump Inhibitor, Buffering
Agent, and Prokinetic Agent

	 	EPO(2)
	 	 	05804774.7	 	 	Abandoned
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	A Novel Formulation, Omeprazole Antacid
Complex-Immediate Release for Rapid and Sustained
Supression of Gastric Acid

	 	EPO(2)
	 	 	04713382.2	 	 	Pending
	 	Santarus and Univ. Missouri (3) (4)
	 
	 	 	 	 	 	 	 	 	 	 
	A Novel Formulation, Omeprazole Antacid
Complex-Immediate Release for Rapid and Sustained
Supression of Gastric Acid

	 	EPO(2)
	 	 	05735477.1	 	 	Pending
	 	Santarus and Univ. Missouri (3) (4)
	 
	 	 	 	 	 	 	 	 	 	 
	Immediate-Release Formulation of acid-Labile
Pharmaceutical Compositions

	 	EPO(2)
	 	 	04778879.9	 	 	Abandoned
	 	Santarus and Univ. Missouri (3) (5)
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Formulations of Proton Pump Inhibitors and
Methods of Using These

	 	EPO(2)
	 	 	07871127.2	 	 	Pending
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Formulations of Proton Pump Inhibitors and
Methods of Using These

	 	GB(2)
	 	GB 0719990.4
	 	Granted
	 	Santarus
	 
	 	 	 	 	 	 	 	 	 	 
	Novel Formulations of Proton Pump Inhibitors and
Methods of Using These

	 	GB(2)
	 	GB 0910544.6
	 	Granted
	 	Santarus

[***]

[***]

[***]

[***]

[***]

[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.exv10w2

Exhibit 10.2

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT

          This FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT (this “Amendment”) is made
as of March 10, 2011 (the “Effective Date”), by and among VeroScience, LLC, a Delaware
limited liability company (“VeroScience”), S2 Therapeutics, Inc. f/k/a Wythe Therapeutics,
Inc., a Tennessee corporation (“S2”), and Santarus, Inc., a Delaware corporation
(“Santarus”). Each of VeroScience, S2 and Santarus is referred to herein individually as a
“party” and collectively as the “parties.”

          WHEREAS, the parties entered into a certain Distribution and License Agreement, dated as of
September 3, 2010 (the “2010 Agreement”); and

          WHEREAS, the parties desire to amend the 2010 Agreement to eliminate certain conditions
precedent to the parties discussion of information relating to and the negotiation of agreements
regarding Additional Products.

          NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants herein
contained, the parties hereto intending to be legally bound hereby agree as follows:

     1. The capitalized terms used but not defined in this Amendment have the meanings ascribed to
such terms in the 2010 Agreement.

     2. The words “after the [***] anniversary of the Effective Date” in the first sentence of
Section 2.5(b) of the 2010 Amendment are hereby replaced with “after [***]”.

     3. With respect to the first Additional Product, [***].

     4. The parties acknowledge and agree that VeroScience’s delivery to Santarus of information
relating to potential reformulation(s) of the Product shall be deemed initiation of discussions
relating to such potential reformulation(s) for the purpose of Section 2.5(b) of the 2010
Agreement. In accordance with Section 2.5(b), subject to the confidentiality provisions of the
2010 Agreement, during the [***] period following the initiation of such discussions pursuant to
Section 2.5(b), VeroScience shall provide to Santarus and S2 such information regarding any such
Development activities or Additional Product(s) as is reasonably requested by Santarus or S2 or as
would reasonably be expected to be material to Santarus’s decision regarding participation in
and/or the provision of financial support for Development associated with such Additional
Product(s), in each case, to the extent VeroScience possesses such information and is not
prohibited from disclosing such information under the terms of an applicable Third Party agreement.

     5. Except as expressly modified in this Amendment, the 2010 Agreement remains in full force
and effect.

     6. This Amendment may be executed in any number of counterparts (including by facsimile or
electronic signature), each of which will be deemed an original as against the party whose
signature appears thereon, but all of which taken together will constitute but one and the same
instrument.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

     7. This Amendment will be construed under and in accordance with, and governed in all respects
by, the laws of the State of New York, without regard to its conflicts of law principles.

[Signature page follows]

 

 

          IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in triplicate as of
the day and year first above written.

	 	 	 	 	 
	 	S2 THERAPEUTICS, INC.

 	 
	 	/S/ Charles P. Sutphin
 	 
	 	By: Charles P. Sutphin 	 
	 	Its: President and Chief Executive Officer 	 
	 
	 	VEROSCIENCE, LLC

 	 
	 	/S/ Anthony H. Cincotta, Ph.D.
 	 
	 	By: Anthony H. Cincotta, Ph.D. 	 
	 	Its: President and Chief Science Officer 	 
	 
	 	SANTARUS, INC.

 	 
	 	/S/ Gerald T. Proehl
 	 
	 	By: Gerald T. Proehl 	 
	 	Its: President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]